^
Association details:
| Biomarker: | MUC16 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | RG7882 (Microtubule inhibitor, MUC16-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
Published date:
10/06/2021
Excerpt:
DMUC4064A was administered once every 3 weeks to patients in 1.0–5.6 mg/kg dose escalation cohorts, followed by cohort expansion at the recommended Phase II dose (RP2D)....Among the 54 patients with high MUC16 immunohistochemistry scores, the clinical benefit rate was 46% (25 patients).
DOI:
https://doi.org/10.1016/j.ygyno.2021.09.023
Trial ID:
